Pharmanutra Croissance future

Future contrôle des critères 4/6

Pharmanutra devrait augmenter ses bénéfices et son chiffre d'affaires de 18.5% et de 13.1% par an respectivement. Le BPA devrait croître de de 1.8% par an. Le rendement des capitaux propres devrait être 29.3% dans 3 ans.

Informations clés

18.5%

Taux de croissance des bénéfices

1.8%

Taux de croissance du BPA

Personal Products croissance des bénéfices	8.0%
Taux de croissance des recettes	13.1%
Rendement futur des capitaux propres	29.3%
Couverture par les analystes	Low
Dernière mise à jour	12 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Sep 11

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Mar 10

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Feb 17

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Feb 01

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Jan 18

Is Pharmanutra (BIT:PHN) A Risky Investment?

Jan 04

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Dec 22

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Dec 08

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 23

Prévisions de croissance des bénéfices et des revenus

BIT:PHN - Estimations futures des analystes et données financières antérieures (EUR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	151	25	24	28	2
12/31/2025	133	22	21	24	2
12/31/2024	117	19	17	20	2
9/30/2024	114	16	19	23	N/A
6/30/2024	108	14	15	20	N/A
3/31/2024	101	11	2	12	N/A
12/31/2023	101	13	-1	12	N/A
9/30/2023	95	12	-5	12	N/A
6/30/2023	93	14	-19	12	N/A
3/31/2023	88	16	-15	14	N/A
12/31/2022	83	15	-9	17	N/A
9/30/2022	79	16	-5	19	N/A
6/30/2022	76	15	10	19	N/A
3/31/2022	73	15	14	20	N/A
12/31/2021	68	14	15	20	N/A
9/30/2021	65	14	13	16	N/A
6/30/2021	60	11	12	15	N/A
3/31/2021	57	14	13	15	N/A
12/31/2020	57	14	10	12	N/A
9/30/2020	58	14	11	11	N/A
6/30/2020	58	14	7	11	N/A
3/31/2020	55	9	4	9	N/A
12/31/2019	54	8	7	12	N/A
9/30/2019	49	8	3	8	N/A
6/30/2019	50	9	7	9	N/A
3/31/2019	48	9	6	8	N/A
12/31/2018	47	9	6	6	N/A
9/30/2018	44	8	5	6	N/A
6/30/2018	41	7	N/A	6	N/A
3/31/2018	40	6	N/A	6	N/A
12/31/2017	38	6	N/A	6	N/A
9/30/2017	37	5	N/A	N/A	N/A
6/30/2017	35	5	N/A	N/A	N/A
3/31/2017	34	4	N/A	N/A	N/A
12/31/2016	33	4	N/A	6	N/A
12/31/2015	26	3	N/A	N/A	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de PHN ( 18.5% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de PHN ( 18.5% par an) devraient croître plus rapidement que le marché Italian ( 7.3% par an).

Croissance élevée des bénéfices: Les bénéfices de PHN devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PHN ( 13.1% par an) devrait croître plus rapidement que le marché Italian ( 4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PHN ( 13.1% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de PHN devrait être élevé dans 3 ans ( 29.3 %)

Pharmanutra Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased to €59.33

Price target increased to €50.67

Price target increased to €45.00

Recent updates

Third quarter 2024 earnings released

Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)

Upcoming dividend of €0.85 per share

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Investor sentiment improved over the past week

Price target increased to €59.33

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to €50.67

Investor sentiment improved over the past week

Price target increased to €45.00

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Upcoming dividend of €0.67 per share

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

New 90-day high: €33.70

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Market bids up stock over the past week

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: €28.80

Third quarter 2020 earnings released: EPS €0.18

New 90-day high: €27.20

First half earnings released

First half earnings released

New 90-day low - €22.40

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance